C07K 14/4747
Apoptosis related proteins
Official title: {Apoptosis related proteins}
C07K14/4747 (Apoptosis related proteins) appears on 802 US grants and 1,181 published applications in this corpus.
Search patents in C07K- Granted patents
- 802
- Published applications
- 1,181
- Assignees
- 571
- Inventors
- 2,164
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 10 | 0 |
| 1998 | 15 | 0 |
| 1999 | 27 | 0 |
| 2000 | 29 | 0 |
| 2001 | 33 | 8 |
| 2002 | 32 | 65 |
| 2003 | 33 | 96 |
| 2004 | 29 | 84 |
| 2005 | 30 | 63 |
| 2006 | 43 | 80 |
| 2007 | 27 | 60 |
| 2008 | 40 | 52 |
| 2009 | 43 | 52 |
| 2010 | 41 | 43 |
| 2011 | 35 | 57 |
| 2012 | 19 | 39 |
| 2013 | 25 | 30 |
| 2014 | 20 | 38 |
| 2015 | 23 | 27 |
| 2016 | 29 | 43 |
| 2017 | 29 | 26 |
| 2018 | 21 | 32 |
| 2019 | 29 | 36 |
| 2020 | 17 | 36 |
| 2021 | 21 | 34 |
| 2022 | 25 | 41 |
| 2023 | 18 | 43 |
| 2024 | 18 | 48 |
| 2025 | 20 | 30 |
| 2026 | 17 | 18 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Selective MCL-1 binding peptides22 Sep 2026US 12,741,997 B2Massachusetts Institute of Technology
- Genetically modified mice having a humanized programmed cell death 1 gene14 Jul 2026US 12,677,813 B2Regeneron Pharmaceuticals, Inc.
- Extracellular vesicles and compositions thereof14 Jul 2026US 12,678,465 B2Exo Biologics SA
- Increased packaging efficiency of vector for cardiac gene therapy30 Jun 2026US 12,667,629 B2University of Florida Research Foundation, Inc.
- Anti-apoptotic vector and method of using the same30 Jun 2026US 12,668,816 B2Wisconsin Alumni Research Foundation
- Novel bax variant and pharmaceutical composition comprising same8 Oct 2026US 2026/0308215 A1Cha University Industry-Academic Cooperation Foundation
- Extracellular Vesicles and Compositions Thereof1 Oct 2026US 2026/0294977 A1Exo Biologics SA
- Compositions and methods for using antigen-specific apoptotic dna immunotherapy to prevent and treat side effects resulting from administration of immune checkpoint inhibitors24 Sep 2026US 2026/0285979 A1Aditxt, Inc.
- Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides6 Aug 2026US 2026/0226104 A1Dana-Farber Cancer Institute, Inc.
- Compound with antitumor activity, corresponding production method and corresponding use30 Jul 2026US 2026/0217776 A1
Most cited
By later US patents
- Vectors and methods for the efficient generation of integration/transgene-free induced pluripotent stem cells from peripheral blood cells126US 9,850,499 B2Loma Linda University · 2017
- Serine substituted mutants of BCL-X.sub.L /BCL-2 associated cell death regulator125US 5,856,445 AWashington University · 1999
- Stabilized alpha helical peptides and uses thereof119US 7,723,469 B2Dana-Farber Cancer Institute, Inc. · 2010
- T cell modifying compounds and uses thereof108US 9,597,357 B2Sangamo BioSciences, Inc. · 2017
- Methods for determining genetic predisposition to autoimmune diseases by genotyping apoptotic genes102US 6,162,604 A2000